Codexis/ US1920051067 /
10/25/2024 9:59:55 PM | Chg. -0.08 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
2.90USD | -2.68% | 35,586 Turnover: 105,214.10 |
-Bid Size: - | -Ask Size: - | 3.09 | 2.90 |
GlobeNewswire
8/20
Codexis to Participate in Enzymatic Synthesis Presentations at RNA Leaders Annual Meeting
GlobeNewswire
7/1
Codexis Finalizes Purchase Agreement with Crosswalk Therapeutics for Gene Therapy Assets
GlobeNewswire
5/14
Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting
GlobeNewswire
5/6
The Benchmark Company Announces Upcoming Healthcare House Call VIRTUAL One-on-One Investor Conferenc...
GlobeNewswire
2/26
Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Ro...
GlobeNewswire
2/20
Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board
GlobeNewswire
2/14
Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28
GlobeNewswire
2/13
Codexis Secures $40 Million in Strategic Financing Deal with Innovatus Capital Partners to Further S...
GlobeNewswire
2/1
seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT Genera...
GlobeNewswire
12/27/2023
Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108
GlobeNewswire
12/13/2023
Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase
GlobeNewswire
12/13/2023
Codexis Announces Achievement of Gram-scale Synthesis with its ECO Synthesis™ Platform